NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $1.17 -0.01 (-0.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.18 +0.02 (+1.28%) As of 03/28/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Silexion Therapeutics Stock (NASDAQ:SLXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.1950-Day Range$0.58▼$3.1452-Week Range$0.58▼$41.85Volume256,498 shsAverage Volume5.99 million shsMarket Capitalization$9.85 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Read More… Remove Ads Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLXN Stock News HeadlinesSilexion Therapeutics announces expanded development plan for SIL204March 28 at 3:24 PM | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28 at 8:30 AM | globenewswire.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 29, 2025 | Porter & Company (Ad)Silexion Therapeutics (NASDAQ:SLXN) Price Target Cut to $5.00 by Analysts at Maxim GroupMarch 23, 2025 | americanbankingnews.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceMarch 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | finanznachrichten.deSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $2.01 on January 1st, 2025. Since then, SLXN shares have decreased by 41.8% and is now trading at $1.17. View the best growth stocks for 2025 here. When did Silexion Therapeutics' stock split? Shares of Silexion Therapeutics reverse split before market open on Friday, November 29th 2024. The 1-9 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. Who are Silexion Therapeutics' major shareholders? Silexion Therapeutics' top institutional investors include Wildcat Capital Management LLC (7.09%). How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Today3/28/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLXN Previous SymbolNASDAQ:SLXN CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+327.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$260,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-249.43% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.80 per share Price / Cash Flow1.46 Book Value($6.63) per share Price / Book-0.18Miscellaneous Outstanding Shares8,415,000Free Float1,074,000Market Cap$9.85 million OptionableN/A Beta0.11 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SLXN) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.